Russia looking for partnership with India for producing COVID-19 vaccine


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ russia-looking-partnership-india-producing-covid19-vaccine
President Vladimir Putin had announced that his country has developed the world's first vaccine against COVID-19

Russia is searching for an association with India for creating COVID-19 antibody Sputnik V, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF), said on Thursday.

Russian President Vladimir Putin had declared that his nation has built up the world's first immunization against COVID-19, which works "adequately" and structures a "steady resistance" against the sickness.

Sputnik V has been created by the Gamaleya Research Institute of Epidemiology and Microbiology, alongside the RDIF. The immunization has not been tried in Phase 3 or bigger clinical preliminaries.

Tending to an online press preparation, Dmitriev said a few countries are keen on the creation of the antibody from nations in Latin America, Asia, and the Middle East.

"The creation of immunization is a significant issue. As of now, we are searching for an association with India. We accept that they are fit for creating the Gamaleya antibody and it is critical to express that those organizations to deliver the immunization will empower us to cover the interest that we have," he said.

Dmitriev said Russia is anticipating universal collaboration.

"We will do clinical preliminaries in Russia as well as in the UAE, Saudi Arabia, presumably in Brazil and India. We are wanting to create the immunization over five nations and there is an appeal from Asia, Latin America, Italy, and different pieces of the world concerning the conveyance of the antibody," he said.

Alexander Ginsburg, the head of the Gamaleya Research Institute of Epidemiology and Microbiology and an academician at the Russian Academy of Sciences, said more than 20,000 individuals have partaken in the clinical preliminaries of antibodies and medications, in light of human adenoviruses or human adenoviral vectors.

"Immunizations don't contain live human adenoviruses, however human adenovirus vectors, that is, human infections that can't duplicate in the body and are sheltered," he said.

The Sputnik V antibody comprises two shots that utilization various adaptations of adenoviruses - infection types, some of which cause the normal cold - that the producers have designed to convey the quality for the surface protein of SARS-CoV-2 that causes COVID-19.

"The methodology of the Gamaleya Institute with the antibody, utilizing two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has an unmistakable favorable position over the one-vector approach utilized by different engineers," Ginsburg said.

Tags : #Russia #India #COVID-19 #Vaccine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026